Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and...
April 02, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require...
March 25, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton Syndrome If Granted Company Would...
March 13, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and...
March 06, 2025 08:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025

ASHBURN, Va., March 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and...
March 04, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Target Indications Include Microcystic Lymphatic Malformations, Venous Malformations and AngiofibromasProprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration Company...
February 27, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Groundbreaking data from first whole body application of QRX003 underscores potential efficacyTransformational improvement in disease state after just 2 weeks of treatment Clear visual evidence of...
February 25, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and...
February 04, 2025 07:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin’s QRX003...
January 23, 2025 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right